Maryland Tech Council CEO, Tami Howie talks with Montgomery County Economic Development Corporation for #MOCO365 on educating, advocating and connecting biotech and tech companies in Maryland.
September 28, 2017 11a PT/ 2p ET
Join us for a web panel discussion on how to successfully move a life science organization from founding to exit. During this discussion, founders will provide guidance on how executive teams can partner business and science together to overcome the stumbling blocks along the way and achieve results. Learn what is real and what is myth!
This summer in the Genetic Engineering & Biotechnology News Annual Rankings of the “Top 10 U.S. Biopharma Clusters”, the BioHealth Capital Region (BHCR) moved up to #5. NIH funding, Venture Capital funding, Patents, Lab Space, and Jobs all are factored into the BHCR’s move into the Top-5.
“Area biopharma leaders have committed to growing their “BioHealth Capital Region” cluster into one of the nation’s top three by 2023, building on anchors ranging from the NIH and FDA, to the nation’s top academic recipient of research grant funding, the Johns Hopkins University. Hopkins accounts for 64.5% of the region’s NIH funding (556 awards totaling $271.4 million), placing fourth with 880 awards totaling nearly $420.7 million. The region is close to meeting its goal in patents (fourth with 4,108), but further back in employment (eighth with 39,145 jobs, according to JLL) and lab space (sixth with 9.5 million square feet).
Vaccine developers continue to grow: In May, Gaithersburg-based Emergent BioSciences opened an $80 million expanded medical countermeasures plant in East Baltimore, while GlaxoSmithKline announced a $139 million capacity expansion at its API plant in Rockville, MD, due to growing demand for its lupus erythematosus treatment Benlysta® (belimumab). The region finished sixth in VC funding last year ($146 million), but climbed to fourth during Q1 (seven awards totaling $71 million). Courting the industry eagerly are both Virginia Gov. Terry McAuliffe (D) and Maryland Gov. Larry Hogan (R), a non-Hodgkin’s lymphoma survivor who calls the cluster-building effort a personal mission.”
We built it, but they didn’t come. In another less-than-glowing analysis of Florida’s innovation economy, the Florida Research Consortium says the state lags in overall number of scientists and in the number of scientists publishing research.
Johns Hopkins University remains the leading patent recipient in the state of Maryland.
Corporate venture capital (CVC) has long been an important source of capital for early-stage biotechs and shows no signs of diminishing, with more and more biopharma companies stepping up their investment activity.
Corporate venture firms are a well-established presence on the biotech funding scene, with the likes of Novartis and Glaxosmithkine’s SR One among the most active investors in the sector. However, the past few years have seen some different names crop up more and more: Pfizer, Celgene and Roche have noticeably stepped up their financing activity, a new analysis by EP Vantage finds.
BioMarker Strategies, LLC, today announced that the Japan Patent Office has granted new patents covering the Company’s SnapPath® Cancer Diagnostics System technology and its PathMAP® Functional Signaling Profile technology.
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Notices
- Notice of Participation of National Institute of Allergy and Infectious Diseases (NIAID) on RFA-CA-17-031 ” Limited Competition: A Data Resource for Analyzing Blood and Marrow Transplants (U24)
- (NOT-AI-17-038)
- National Institute of Allergy and Infectious Diseases
- Notice of Applicant Information Webinar for the Point-of-Care Technologies Research Network Centers (U54)
- (NOT-EB-17-010)
- National Institute of Biomedical Imaging and Bioengineering
- Notice of Intent to Publish: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38)
- (NOT-HL-17-533)
- National Heart, Lung, and Blood Institute
- Notice Announcing an Applicant Information Webinar for Phase II of the Undiagnosed Diseases Network (RFA-RM-17-019, RFA-RM-17-018, RFA-RM-17-017, RFA-RM-17-016, RFA-RM-17-015)”
- (NOT-RM-17-038)
- NIH Roadmap Initiatives
Requests for Applications
- Stimulating Access to Research in Residency (StARR) (R38)
- (RFA-HL-18-023)
- National Heart, Lung, and Blood Institute
Program Announcements
- Continuation of Existing Grant Based Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases and Disorders (U01)
- (PAR-17-338)
- National Heart, Lung, and Blood Institute
- Clinical and Epidemiological Research on Chronic Disease in the Caribbean (R01)
- (PAR-17-470)
- National Heart, Lung, and Blood Institute
The MOVE program is an innovative approach intended to attract new businesses to Montgomery County, Maryland. Eligible new businesses will receive a one-time grant upon signing a commercial lease within the county.
Businesses new to the county that lease up to 20,000 square feet of Class A or B office space may receive a grant of $8/sf. All grants are capped at 10,000 square feet for purposes of calculating the grant award.